Enjoy complimentary customisation on priority with our Enterprise License!
Epilepsy is a group of varying disorders that has life-threatening symptoms. It is generally caused by brain deformities and is characterized by the frequent occurrence of generalized or partial seizures. The market for epilepsy drugs in Europe is positively influenced by the adoption of reformulation strategies by vendors and is expected to surpass US$ 1,100 million by 2019.
In this market research report, analysts have estimated factors like the unmet medical needs of patients in Europe to positively drive market growth during the forecast period. At present, the drugs that are administered during epilepsy fail drastically to check the progression of the disease and may lead to complications like weight gain, blurred vision, and dizziness. The unavailability of effective drugs for treating epilepsy will provide vendors the opportunity to design effective disease-modifying therapies that will spur market growth.
First-generation anti-epileptic drugs include compounds like benzodiazepines, carbamazepine, and phenytoin. Drugs like phenytoin function by inducing the CYP enzyme, which then triggers drug-drug interactions. However, these drugs have to be monitored closely and may often lead to life-threatening reactions.
This market is dominated by large vendors like Eisai, GlaxoSmithKline, Pfizer, and UCB. The recent increase in patient population and the expected launch of promising pipeline drugs during the forecast period are expected to spur the revenues generated by the companies.
Leading vendors in this market are –
Other prominent vendors in this market are AbbVie, Roche, Lundbeck, Janssen Pharmaceuticals, Meda, Novartis, Shire, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Upsher-Smith, and Valeant Pharmaceuticals.
Upcoming trends like the advent of new-generation anti-epileptic drugs is expected to foster market growth as they have a superior pharmacokinetic profile when compared to conventional drugs. As these drugs have little or no side effects, they are rapidly gaining acceptance in various territories.
This report provides a number of factors contributing to the adoption, limitations, and opportunities of the epilepsy drugs market in Europe. It also offers an analysis of each factor and an estimation of the extent to which the factors are likely to impact the overall market growth.
Technavio also offers customization on reports based on specific client requirement.
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.